Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer';s Disease
The DOI matches its Crossref record.
Abstract
Resveratrol (3,4',5-trihydroxystilbene) is a naturally occurring phytochemical present in red wine, grapes, berries, chocolate and peanuts. Clinically, resveratrol has exhibited significant antioxidant, anti-inflammatory, anti-viral, and anti-cancer properties. Although resveratrol was first isolated in 1940, it was not until the last decade that it was recognised for its potential therapeutic role in reducing the risk of neurodegeneration, and Alzheimer's disease (AD) in particular. AD is the primary cause of progressive dementia. Resveratrol has demonstrated neuroprotective effects in several in vitro and in vivo models of AD. Apart from its potent antioxidant and anti-inflammatory roles, evidence suggests that resveratrol also facilitates non-amyloidogenic breakdown of the amyloid precursor protein (APP), and promotes removal of neurotoxic amyloid beta (Aβ) peptides, a critical step in preventing and slowing down AD pathology. Resveratrol also reduces damage to neuronal cells via a variety of additional mechanisms, most notably is the activation of NAD(+)-dependent histone deacetylases enzymes, termed sirtuins. However in spite of the considerable advances in clarifying the mechanism of action of resveratrol, it is unlikely to be effective as monotherapy in AD due to its poor bioavailability, biotransformation, and requisite synergism with other dietary factors. This review summarizes the relevance of resveratrol in the pathophysiology of AD. It also highlights why resveratrol alone may not be an effective single therapy, and how resveratrol coupled to other compounds might yet prove an effective therapy with multiple targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
González-Sarrías, A., Núñez-Sánchez, M. A., Tomás-Barberán, F. A., & Espín, J. C. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04538 · Cited by 174
Role of natural products for the treatment of Alzheimer’s disease
Noori, T., Dehpour, A. R., Sureda, A., Sobarzo-Sanchez, E., & Shirooie, S. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173974 · Cited by 141
Plants-derived neuroprotective agents: cutting the cycle of cell death through multiple mechanisms
Elufioye, T. O., Berida, T. I., & Habtemariam, S. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/3574012 · Cited by 107
Wei, Z., Chen, X.-C., Song, Y., Pan, X.-D., Dai, X.-M., Zhang, J., Cui, X.-L., Wu, X.-L., & Zhu, Y.-G. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.186646 · Cited by 89
“[44] Thus, from this perspective, anti‐aging molecules with antioxidant properties, such as sirtuins,[45,46] coenzyme Q10,[47] glutathione,[48] ginsenoside Rg1,[49] resveratrol,[50] and lifestyle impact, for instance, exercise[51] and drinking green tea, will present as potential and promising neuronal protectants for…”
BackgroundMurakami, K., & Irie, K. (2019) · Molecules · doi:10.3390/molecules24112125 · Cited by 31
Metadata
- Authors
- Braidy, N., Jugder, B.-E., Poljak, A., Jayasena, T., Mansour, H., Mohammad Nabavi, S., Sachdev, P., & Grant, R.
- Venue
- Current Topics in Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2016-04-29
- Volume
- 16
- Issue
- 17
- Pages
- 1951-1960
- ISSN
- 1568-0266 (ISSN-L)
- OpenAlex
- W2325685234
- Cited by
- 88
- References
- 0
- FWCI
- 7.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer';s Disease. https://app.cochat.ai/papers/10.2174/1568026616666160204121431
- The paper
- Braidy, N., Jugder, B.-E., Poljak, A., Jayasena, T., Mansour, H., Mohammad Nabavi, S., Sachdev, P., & Grant, R. (2016). Resveratrol as a Potential Therapeutic Candidate for the Treatment and Management of Alzheimer';s Disease. Current Topics in Medicinal Chemistry. https://doi.org/10.2174/1568026616666160204121431
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.